Adage Capital Partners
SABS icon

Adage Capital Partners’s SAB Biotherapeutics SABS Stock Holding History

Adage Capital Partners’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25M Buy
6,405,553
+3,000,000
+88% +$11.2M 0.04% 437
2026
Q1 		$13M Buy
+3,405,553
New +$13.6M 0.02% 621

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Adage Capital Partners's SABS Position: Q2 2026 in Review

Adage Capital Partners increased its SAB Biotherapeutics (SABS) stake by 88% in Q2 2026, buying an estimated $11.2M and bringing the position to 6,405,553 shares worth $25M. The position accounts for 0.04% of the portfolio, ranked #437.

Adage Capital Partners first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Adage Capital Partners held 6,405,553 shares of SAB Biotherapeutics worth $25M as of Q2 2026.
  • Adage Capital Partners bought 3,000,000 SAB Biotherapeutics shares in Q2 2026, an estimated $11.2M.
  • SAB Biotherapeutics made up 0.04% of Adage Capital Partners's portfolio in Q2 2026, its #437 holding.
  • Adage Capital Partners first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.